Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 16:59 ET | Source: Shattuck Labs, Inc. AUSTIN, TX…
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq:…
PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 20, 2024 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
December 12, 2024 06:00 ET | Source: Keros Therapeutics, Inc. Keros will…
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or…
GEn1E Lifesciences appoints Franois Nader, MD as Chair of its Board of Directors
Former CEO of NPS Pharma brings strong biotech expertise to further accelerate…